MicroRNA signatures as clinical biomarkers in lung cancer

References

• Herbst RS, Heymach JV, Lippman SM. Lung cancer. N Engl J Med. 2008;359:1367–1380.
   PubMed Web of Science ®Google Scholar
• Feinstein AR, Gelfman NA, Yesner R. Observer variability in the histopathologic diagnosis of lung cancer. Am Rev Respir Dis. 1970;101(5):671–684.
   Google Scholar
• Travis WD, Travis LB, Devesa SS. Lung cancer. Cancer. 1995;75:191–202.
   PubMed Web of Science ®Google Scholar
• Van Roosbroeck K, Pollet J, Calin GA. miRNAs and long noncoding RNAs as biomarkers in human diseases. Expert Rev Mol Diagn. 2013; 13(2):183–204.
   PubMed Web of Science ®Google Scholar
• Ling H, Fabbri M, Calin GA. MicroRNAs and other non-coding RNAs as targets for anticancer drug development. Nat Rev Drug Discov. 2013;12(11):847–865.
   PubMed Web of Science ®Google Scholar
• Lianidou ES, Strati A, Markou A. Circulating tumor cells as promising novel biomarkers in solid cancers. Crit Rev Clin Lab Sci. 2014;51(3):160–171.
   PubMed Web of Science ®Google Scholar
• Alix-Panabières C, Pantel K. Circulating tumor cells: liquid biopsy of cancer. Clin Chem. 2013;59:110–118.
   PubMed Web of Science ®Google Scholar
• Plaks V, Koopman C, Werb Z. Circulating tumor cells. Science. 2013; 341(6151):1186–1188.
   PubMed Web of Science ®Google Scholar
• Marzese DM, Hirose H, Hoon DS. Diagnostic and prognostic value of circulating tumor-related DNA in cancer patients. Expert Rev Mol Diagn. 2013;13(8):827–844.
   PubMed Web of Science ®Google Scholar
• Schwarzenbach H, Nishida N, Calin GA, Pantel K. Clinical relevance of circulating cell-free microRNAs in cancer. Nat Rev Clin Oncol. 2014;11(3):145–156.
   PubMed Web of Science ®Google Scholar
• Calin GA, Dumitru CD, Shimizu M, et al. Frequent deletions and down-regulation of micro-RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia. Proc Natl Acad Sci U S A. 2002;99(24):15524–15529.
   PubMed Web of Science ®Google Scholar
• Ell B, Kang Y. MicroRNAs as regulators of bone homeostasis and bone metastasis. Bonekey Rep. 2014;3:549.
   PubMedGoogle Scholar
• Cheng Z, Ma R, Tan W, Zhang L. MiR-152 suppresses the proliferation and invasion of NSCLC cells by inhibiting FGF2. Exp Mol Med. 2014;46:e112.
   Google Scholar
• Yu S, Zhang C, Deng F, Zhang Y. miR-99a suppresses the metastasis of human non- small cell lung cancer cells by targeting AKT1 signaling pathway. J Cell Biochem. Epub September 4, 2014.
   Google Scholar
• Gu Y, Cheng Y, Song Y, et al. MicroRNA-493 suppresses tumor growth, invasion and metastasis of lung cancer by regulating E2F1. PLoS One. 2014;9(8):e102602.
   Web of Science ®Google Scholar
• Liu C, Yang H, Xu Z, et al. microRNA-548l is involved in the migration and invasion of non-small cell lung cancer by targeting the AKT1 signaling pathway. J Cancer Res Clin Oncol. Epub September 23, 2014.
   Google Scholar
• Lodes MJ, Caraballo M, Suciu D, Munro S, Kumar A, Anderson B. Detection of cancer with serum miRNAs on an oligonucleotide microarray. PLoS One. 2009;4(7):e6229.
   PubMed Web of Science ®Google Scholar
• Lu J, Getz G, Miska EA, et al. MicroRNA expression profiles classify human cancers. Nature. 2005;435(7043):834–838.
   PubMed Web of Science ®Google Scholar
• Markou A, Liang Y, Lianidou E. Prognostic, therapeutic and diagnostic potential of microRNAs in non-small cell lung cancer. Clin Chem Lab Med. 2011;49(10):1591–1603.
   Web of Science ®Google Scholar
• Peng Y, Dai Y, Hitchcock C, et al. Insulin growth factor signaling is regulated by microRNA-486, an underexpressed microRNA in lung cancer. Proc Natl Acad Sci U S A. 2013;110(37):15043–15048.
   PubMed Web of Science ®Google Scholar
• Zhao B, Han H, Chen J, et al. MicroRNA let-7c inhibits migration and invasion of human non-small cell lung cancer by targeting ITGB3 and MAP4K3. Cancer Lett. 2014;342(1):43–51.
   Web of Science ®Google Scholar
• Xia Y, Wu Y, Liu B, Wang P, Chen Y. Downregulation of miR-638 promotes invasion and proliferation by regulating SOX2 and induces EMT in NSCLC. FEBS Lett. 2014;588(14):2238–2245.
   PubMed Web of Science ®Google Scholar
• Ma Q, Jiang Q, Pu Q, et al. MicroRNA-143 inhibits migration and invasion of human non-small-cell lung cancer and its relative mechanism. Int J Biol Sci. 2013;9(7):680–692.
   PubMed Web of Science ®Google Scholar
• Garofalo M, Jeon YJ, Nuovo GJ, et al. MiR-34a/c-dependent PDGFR-α/β downregulation inhibits tumorigenesis and enhances TRAIL-induced apoptosis in lung cancer. PLoS One. 2013;8(6):e67581.
   Web of Science ®Google Scholar
• Romano G, Acunzo M, Garofalo M, et al. MiR-494 is regulated by ERK1/2 and modulates TRAIL-induced apoptosis in non-small-cell lung cancer through BIM down-regulation. Proc Natl Acad Sci U S A. 2012;109(41):16570–16575.
   PubMed Web of Science ®Google Scholar
• Acunzo M, Romano G, Palmieri D, et al. Cross-talk between MET and EGFR in non- small cell lung cancer involves miR-27a and Sprouty2. Proc Natl Acad Sci U S A. 2013;110(21):8573–8578.
   PubMed Web of Science ®Google Scholar
• Gao W, Shen H, Liu L, Xu J, Xu J, Shu Y. MiR-21 overexpression in human primary squamous cell lung carcinoma is associated with poor patient prognosis. J Cancer Res Clin Oncol. 2011;137(4):557–566.
   PubMed Web of Science ®Google Scholar
• Markou A, Tsaroucha EG, Kaklamanis L, Fotinou M, Georgoulias V, Lianidou ES. Prognostic value of mature microRNA-21 and microRNA-205 overexpression in non-small cell lung cancer by quantitative real-time RT-PCR. Clin Chem. 2008;54(10):1696–1704.
   PubMed Web of Science ®Google Scholar
• Saito M, Schetter AJ, Mollerup S, et al. The association of microRNA expression with prognosis and progression in early-stage, non-small cell lung adenocarcinoma: a retrospective analysis of three cohorts. Clin Cancer Res. 2011;17(7):1875–1882.
   PubMed Web of Science ®Google Scholar
• Lu Y, Govindan R, Wang L, et al. MicroRNA profiling and prediction of recurrence/relapse-free survival in stage I lung cancer. Carcinogenesis. 2012;33(5):1046–1054.
   PubMed Web of Science ®Google Scholar
• Hu J, Cheng Y, Li Y, et al. microRNA-128 plays a critical role in human non-small cell lung cancer tumourigenesis, angiogenesis and lymphangiogenesis by directly targeting vascular endothelial growth factor-C. Eur J Cancer. 2014;50(13):2336–2350.
   Web of Science ®Google Scholar
• Bjaanaes MM, Halvorsen AR, Solberg S, et al. Unique microRNA-profiles in EGFR- mutated lung adenocarcinomas. Int J Cancer. 2014; 135(8):1812–1821.
   Web of Science ®Google Scholar
• Kim J, Lim NJ, Jang SG, Kim HK, Lee GK. miR-592 and miR-552 can distinguish between primary lung adenocarcinoma and colorectal cancer metastases in the lung. Anticancer Res. 2014;34(5):2297–2302.
   Web of Science ®Google Scholar
• Meng W, Ye Z, Cui R, et al. MicroRNA-31 predicts the presence of lymph node metastases and survival in patients with lung adenocarcinoma. Clin Cancer Res. 2013;19(19):5423–5433.
   PubMed Web of Science ®Google Scholar
• Molina-Pinelo S, Gutiérrez G, Pastor MD, et al. MicroRNA-dependent regulation of transcription in non-small cell lung cancer. PLoS One. 2014;9(3):e90524.
   Web of Science ®Google Scholar
• Sun Y, Su B, Zhang P, et al. Expression of miR-150 and miR-3940-5p is reduced in non-small cell lung carcinoma and correlates with clinicopathological features. Oncol Rep. 2013;29(2):704–712.
   PubMed Web of Science ®Google Scholar
• Võsa U, Vooder T, Kolde R, Vilo J, Metspalu A, Annilo T. Meta-analysis of microRNA expression in lung cancer. Int J Cancer. 2013;132(12):2884–2893.
   PubMed Web of Science ®Google Scholar
• Yang M, Shen H, Qiu C, et al. High expression of miR-21 and miR-155 predicts recurrence and unfavourable survival in non-small cell lung cancer. Eur J Cancer. 2013;49(3):604–615.
   PubMed Web of Science ®Google Scholar
• Zhu W, Liu X, He J, Chen D, Hunag Y, Zhang YK. Overexpression of members of the microRNA-183 family is a risk factor for lung cancer: a case control study. BMC Cancer. 2011;11:393.
   PubMed Web of Science ®Google Scholar
• Liu XG, Zhu WY, Huang YY, et al. High expression of serum miR-21 and tumor miR-200c associated with poor prognosis in patients with lung cancer. Med Oncol. 2012;29(2):618–626.
   PubMed Web of Science ®Google Scholar
• Markou A, Sourvinou I, Vorkas PA, Yousef GM, Lianidou E. Clinical evaluation of microRNA expression profiling in non-small-cell lung cancer. Lung Cancer. 2013;81(3):388–396.
   PubMed Web of Science ®Google Scholar
• Zhu WY, Luo B, An JY, et al. Differential Expression of miR-125a-5p and let-7e predicts the progression and prognosis of non-small-cell lung cancer. Cancer Invest. 2014;32(8):394–401.
   PubMed Web of Science ®Google Scholar
• Zhu W, He J, Chen D, et al. Expression of miR-29c, miR-93, and miR-429 as potential biomarkers for detection of early stage non-small lung cancer. PLoS One. 2014;9(2):e87780.
   PubMed Web of Science ®Google Scholar
• Li X, Shi Y, Yin Z, Xue X, Zhou B. An eight-miRNA signature as a potential biomarker for predicting survival in lung adenocarcinoma. J Transl Med. 2014;12:159.
   PubMed Web of Science ®Google Scholar
• Ma J, Mannoor K, Gao L, et al. Characterization of microRNA transcriptome in lung cancer by next-generation deep sequencing. Mol Oncol. 2014;8(7):1208–1219.
   PubMed Web of Science ®Google Scholar
• Yu H, Jiang L, Sun C, et al. Decreased circulating miR-375: a potential biomarker for patients with non-small-cell lung cancer. Gene. 2014;534(1):60–65.
   PubMed Web of Science ®Google Scholar
• Li Y, Liang L, Zhang CY. Isothermally sensitive detection of serum circulating miRNAs for lung cancer diagnosis. Anal Chem. 2013;85(23):11174–11179.
   Web of Science ®Google Scholar
• Rani S, Gately K, Crown J, O’Byrne K, O’Driscoll L. Global analysis of serum microRNAs as potential biomarkers for lung adenocarcinoma. Cancer Biol Ther. 2013;14(12):1104–1112.
   PubMed Web of Science ®Google Scholar
• Kaduthanam S, Gade S, Meister M, et al. Serum miR-142-3p is associated with early relapse in operable lung adenocarcinoma patients. Lung Cancer. 2013;80(2):223–227.
   PubMed Web of Science ®Google Scholar
• Mitchell PS, Parkin RK, Kroh EM, et al. Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci U S A. 2008;105(30):10513–10518.
   PubMed Web of Science ®Google Scholar
• Sourvinou IS, Markou A, Lianidou ES. Quantification of circulating miRNAs in plasma: effect of preanalytical and analytical parameters on their isolation and stability. J Mol Diagn. 2013;15(6):827–834.
   PubMed Web of Science ®Google Scholar
• Cheng HH, Yi HS, Kim Y, et al. Plasma processing conditions substantially influence circulating microRNA biomarker levels. PLoS One. 2013;8(6):e64795.
   PubMed Web of Science ®Google Scholar
• Heegaard NH, Schetter AJ, Welsh JA, Yoneda M, Bowman ED, Harris CC. Circulating micro-RNA expression profiles in early stage nonsmall cell lung cancer. Int J Cancer. 2012;130(6):1378–1386.
   PubMed Web of Science ®Google Scholar
• Keller A, Backes C, Leidinger P, et al. Next-generation sequencing identifies novel microRNAs in peripheral blood of lung cancer patients. Mol Biosyst. 2011;7(12):3187–3199.
   PubMed Web of Science ®Google Scholar
• Wang Y, Gu J, Roth JA, et al. Pathway-based serum microRNA profiling and survival in patients with advanced stage non-small cell lung cancer. Cancer Res. 2013;73(15):4801–4809.
   PubMed Web of Science ®Google Scholar
• Lin Q, Chen T, Lin Q, et al. Serum miR-19a expression correlates with worse prognosis of patients with non-small cell lung cancer. J Surg Oncol. 2013;107(7):767–771.
   Web of Science ®Google Scholar
• Sanfiorenzo C, Ilie MI, Belaid A, et al. Two panels of plasma microRNAs as non-invasive biomarkers for prediction of recurrence in resectable NSCLC. PLoS One. 2013;8(1):e54596.
   PubMed Web of Science ®Google Scholar
• Chen Q, Si Q, Xiao S, et al. Prognostic significance of serum miR-17-5p in lung cancer. Med Oncol. 2013;30(1):353.
   PubMed Web of Science ®Google Scholar
• Fortunato O, Boeri M, Verri C, et al. Assessment of circulating microRNAs in plasma of lung cancer patients. Molecules. 2014;19(3):3038–3054.
   PubMed Web of Science ®Google Scholar
• Rani S, Gately K, Crown J, O’Byrne K, O’Driscoll L. Global analysis of serum microRNAs as potential biomarkers for lung adenocarcinoma. Cancer Biol Ther. 2013;14(12):1104–1112.
   PubMed Web of Science ®Google Scholar
• Mozzoni P, Banda I, Goldoni M, et al. Plasma and EBC microRNAs as early biomarkers of non-small-cell lung cancer. Biomarkers. 2013;18(8):679–686.
   PubMed Web of Science ®Google Scholar
• Tang D, Shen Y, Wang M, et al. Identification of plasma microRNAs as novel noninvasive biomarkers for early detection of lung cancer. Eur J Cancer Prev. 2013;22(6):540–548.
   PubMed Web of Science ®Google Scholar
• Ulivi P, Foschi G, Mengozzi M, et al. Peripheral blood miR-328 expression as a potential biomarker for the early diagnosis of NSCLC. Int J Mol Sci. 2013;14(5):10332–10342.
   PubMed Web of Science ®Google Scholar
• Zheng D, Haddadin S, Wang Y, et al. Plasma microRNAs as novel biomarkers for early detection of lung cancer. Int J Clin Exp Pathol. 2011;4(6):575–586.
   PubMed Web of Science ®Google Scholar
• Wu R, Jiang Y, Wu Q, et al. Diagnostic value of microRNA-21 in the diagnosis of lung cancer: evidence from a meta-analysis involving 11 studies. Tumour Biol. 2014;35(9):8829–8836.
   PubMedGoogle Scholar
• Shen Y, Wang T, Yang T, et al. Diagnostic value of circulating microRNAs for lung cancer: a meta-analysis. Genet Test Mol Biomarkers. 2013;17(5):359–366.
   Web of Science ®Google Scholar
• Bianchi F, Nicassio F, Marzi M, et al. A serum circulating miRNA diagnostic test to identify asymptomatic high-risk individuals with early stage lung cancer. EMBO Mol Med. 2011;3(8):495–503.
   PubMed Web of Science ®Google Scholar
• Skrzypski M, Czapiewski P, Goryca K, et al. Prognostic value of microRNA expression in operable non-small cell lung cancer patients. Br J Cancer. 2014;110(4):991–1000.
   Web of Science ®Google Scholar
• Li ZH, Zhang H, Yang ZG, Wen GQ, Cui YB, Shao GG. Prognostic significance of serum microRNA-210 levels in non-small-cell lung cancer. J Int Med Res. 2013;41(5):1437–1444.
   Web of Science ®Google Scholar
• Franchina T, Amodeo V, Bronte G, et al. Circulating miR-22, miR-24 and miR-34a as novel predictive biomarkers to pemetrexed-based chemotherapy in advanced non-small cell lung cancer. J Cell Physiol. 2014;229(1):97–99.
   PubMed Web of Science ®Google Scholar
• Patnaik SK, Yendamuri S, Kannisto E, Kucharczuk JC, Singhal S, Vachani A. MicroRNA expression profiles of whole blood in lung adenocarcinoma. PLoS One. 2012;7(9):e46045.
   PubMed Web of Science ®Google Scholar
• Liao QB, Guo JQ, Zheng XY, et al. Test performance of sputum microRNAs for lung cancer: a meta-analysis. Genet Test Mol Biomarkers. 2014;18(8):562–567.
   Web of Science ®Google Scholar
• Shin YM, Yun J, Lee OJ, et al. Diagnostic value of circulating extracellular miR-134, miR-185, and miR-22 levels in lung adenocarcinoma-associated malignant pleural effusion. Cancer Res Treat. 2014;46(2):178–185.
   PubMed Web of Science ®Google Scholar
• Xie Y, Todd NW, Liu Z, et al. Altered miRNA expression in sputum for diagnosis of non-small cell lung cancer. Lung Cancer. 2010;67(2):170–176.
   PubMed Web of Science ®Google Scholar
• Li N, Ma J, Guarnera MA, Fang H, Cai L, Jiang F. Digital PCR quantification of miRNAs in sputum for diagnosis of lung cancer. J Cancer Res Clin Oncol. 2014;140(1):145–150.
   PubMed Web of Science ®Google Scholar
• Shen J, Liao J, Guarnera MA, et al. Analysis of MicroRNAs in sputum to improve computed tomography for lung cancer diagnosis. J Thorac Oncol. 2014;9(1):33–40.
   PubMed Web of Science ®Google Scholar
• Sato-Kuwabara Y, Melo SA, Soares FA, Calin GA. The fusion of two worlds: non-coding RNAs and extracellular vesicles – diagnostic and therapeutic implications (review). Int J Oncol. 2015;46(1):17–27.
   PubMed Web of Science ®Google Scholar
• Mello SA, Sugimoto H, O’Connell JT, et al. Cancer exosomes perform cell-independent microRNA biogenesis and promote tumorigenesis. Cancer Cell. 2014;26(5):707–721.
   Web of Science ®Google Scholar
• Rabinowits G, Gerçel-Taylor C, Day JM, Taylor DD, Kloecker GH. Exosomal microRNA: a diagnostic marker for lung cancer. Clin Lung Cancer. 2009;10(1):42–46.
   PubMed Web of Science ®Google Scholar
• Frydrychowicz M, Kolecka-Bednarczyk A, Madejczyk M, Yasar S, Dworacki G. Exosomes – structure, biogenesis, and biological role in non-small-cell lung cancer. Scand J Immunol. Epub October 30, 2014.
   Google Scholar
• Leidinger P, Backes C, Dahmke IN, et al. What makes a blood cell based miRNA expression pattern disease specific? – a miRNome analysis of blood cell subsets in lung cancer patients and healthy controls. Oncotarget. 2014;5(19):9484–9497.
   PubMedGoogle Scholar
• Rodríguez M, Silva J, López-Alfonso A, et al. Different exosome cargo from plasma/bronchoalveolar lavage in non-small-cell lung cancer. Genes Chromosomes Cancer. 2014;53(9):713–724.
   PubMed Web of Science ®Google Scholar
• Nana-Sinkam SP, Croce CM. Clinical applications for microRNAs in cancer. Clin Pharmacol Ther. 2012;93(1):98–104.
   Web of Science ®Google Scholar